A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties

Nature Medicine

Volumn 15, Issue 9, 2009, Pages 1038-1045

  Rafei, Moutih ^a   Hsieh, Jeremy ^a   Zehntner, Simone ^b,c   Li, Mengyang ^a   Forner, Kathy ^a   Birman, Elena ^a   Boivin, Marie Noëlle ^a   Young, Yoon Kow ^a   Perreault, Claude ^d   Galipeau, Jacques ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 15 FUSOKINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAT6 PROTEIN; SYNDECAN 1; TRANSCRIPTION FACTOR PAX5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOTRANSPLANTATION; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; ONTOGENY; PHENOTYPE; PRIORITY JOURNAL; REGULATORY B LYMPHOCYTE; REMISSION; SPLEEN CELL; UPREGULATION;

ANIMALS; B-LYMPHOCYTE SUBSETS; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-15; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; STAT6 TRANSCRIPTION FACTOR; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

MUS;

EID: 69949153114     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2003     Document Type: Article

References (35)

1. 1. Kuhlmann, T. et al. Continued administration of ciliary neurotrophic factor protects mice from Inflammatory pathology in experimental autoimmune encephalomyelitis. Am. J. Pathol. 169, 584-598 (2006). (Pubitemid 44156316)
2. Jack, C., Ruffini, F., Bar-Or, A. & Antel, J.P. Microglia and multiple sclerosis. J. Neurosci. Res. 81, 363-373 (2005).
3. 3. O'Connor, K.C., Bar-Or, A. & Hafler, D.A. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes In immunopathogenesls. J. Clin. Immunol. 21, 81-92 (2001 (Pubitemid 32328759)
4. The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsingremltting multiple sclerosis. I. Clinical results of a multlcenter, randomized, doubleblind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43, 655-661 (1993).
5. 5. Panitch, H., Miller, A., Paty, D. & Weinshenker, B. Interferon β-1b In secondary progressive MS: results from a 3-year controlled study. Neurology 63, 1788-1795 (2004). (Pubitemid 39532370)
6. Johnson, K.P. et al. Copolymer 1 reduces relapse rate and Improves disability In relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45, 1268-1276 (1995).
7. Hartung, H.P. et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet 360, 2018-2025 (2002).
8. 8. Krapf, H. et al. Effect of mitoxantrone on MRI In progressive MS: results of the MIMS trial. Neurology 65, 690-695 (2005). (Pubitemid 41285846)
9. Polman, CH. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
10. Dhlb-Jalbut, S. et al. Effect of combined IFNβ-1a and glatlramer acetate therapy on GA-specific T cell responses In multiple sclerosis. Mult. Scler. 8, 485-491 (2002).
11. Arnold, D.L. et al. Glatlramer acetate after mltoxantrone induction improves MRI markers of lesion volume and permanent tissue Injury in MS. J. Neurol. 255, 1473-1478 (2008).
12. Stern, J.N. et al. Amino acid copolymerspecific IL-10-secretlng regulatory T cells that ameliorate autoimmune diseases In mice. Proc. Natl. Acad. Sci. USA 105, 5172-5176 (2008).
13. + regulatory T cells In nonlymphopenlc hosts. J. Leukoc. Biol. 82, 1053-1061 (2007).
14. + regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigenspecific reactivation in vivo Is critical for bystander regulation. Blood 105, 4871-4877 (2005).
15. 15. Fassas, A. et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multlcenter study. J. Neurol. 249, 1088-1097 (2002). (Pubitemid 35002235)
16. 16. Rafei, M. et al. GM-CSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood 109, 2234-2242 (2007). (Pubitemid 46348228)
17. 17. Horcher, M., Souabni, A. & Bussllnger, M. Pax5/BSAP maintains the identity of B cells In late B lymphopoiesis. Immunity 14, 779-790 (2001). (Pubitemid 32592424)
18. kBpPathway In TLR-stimulated human monocytes and macrophages. J. Immunol. 181, 8018-8026 (2008).
19. 19. Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D. & Anderton, S.M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944-950 (2002). (Pubitemid 35154008)
20. 20. Kitamura, D., Roes, J., Kuhn, R. & Rajewsky, K.A. B cell-deficient mouse by targeted disruption of the membrane exon of the Immunoglobulin mu chain gene. Nature 350, 423-426 (1991). (Pubitemid 21912244)
21. Wolf, S.D., Dittel, B.N., Hardardottlr, F. & Janeway, CA. Jr. Experimental autoimmune encephalomyelitis induction In genetically B cell-deficient mice. J. Exp. Med. 184, 2271-2278 (1996).
22. Matsushita, T., Yanaba, K., Bouaziz, J.D., Fujimoto, M. & Tedder, T.F. Regulatory B cells Inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430 (2008).
23. + phenotype controls T cell-dependent Inflammatory responses. Immunity 28, 639-650 (2008).
24. Evans, J.G. et al. Novel suppressive function of transitional 2 B cells In experimental arthritis. J. Immunol. 178, 7868-7878 (2007).
25. 25. Mauri, C., Mars, L.T. & Londel, M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune Inflammatory process. Nat. Med. 6, 673-679 (2000). (Pubitemid 30398791)
26. Lau, A.W., Blester, S., Cornall, R.J. & Forrester, J.V. Lipopolysaccharlde-activated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinltis by MHCII-dependent activation of CD62L-expresslng regulatory T cells. J. Immunol. 180, 3889-3899 (2008).
27. 27. Brummel, R. & Lenert, P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-ollgodeoxynucleotldes. J. Immunol. 174, 2429-2434 (2005). (Pubitemid 40223993)
28. Fornek, J.L. et al. Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood 107, 1085-1091 (2006).
29. Bouaziz, J.D., Yanaba, K. & Tedder, T.F. Regulatory B cells as Inhibitors of immune responses and Inflammation. Immunol. Rev. 224, 201-214 (2008).
30. Singh, A.K. et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194, 1801-1811 (2001).
31. + T regulatory cells and IL-10 via B7 Is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol. 178, 3447-3456 (2007).
32. 32. Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R.S. & Bhan, A.K. Chronic Intestinal inflammatory condition generates IL-10-produclng regulatory B cell subset characterized by CDId upregulatlon. Immunity 16, 219-230 (2002). (Pubitemid 34211962)
33. Singh, A. et al. Regulatory role of B cells In a murine model of allergic airway disease. J. Immunol. 180, 7318-7326 (2008).
34. Jamln, C. et al. Regulatory B lymphocytes in humans: A potential role in autoimmunity. Arthritis Rheum. 58, 1900-1906 (2008).
35. Rafei, M. et al. Selective Inhibition of CCR2 expressing cells In experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine. J. Immunol. 182, 2620-2627 (2009).